List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
Professor Sir John Bell, Regius Professor of Medicine at the University of Oxford, delivered a speech at the MHRA’s 14th Annual Lecture in London, outlining his vision for the UK life sciences industry. Here, Nikki Withers summarises the key take-home messages from the talk, including how UK researchers and investors…
A study has demonstrated the success of changing the genome of mice, regulating the production of the C11orf46 gene.
A new study has shown that a Class 1 CRISPR gene editing system can achieve functional DNA repairs in human cells with no prominent off-target effects.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
Researchers have announced the creation of a novel technique for screening CRISPR edits that allows scientists to identify unintended outcomes in the genome.
Researchers have created ‘three-parent flies' which can be used as a model to study mitochondrial diseases and screen potential drug compounds.
Scientists have shown that the mutated CUL3 gene, which is involved in the cell’s clearance of proteins, plays a role in the development of autism and schizophrenia in mice.
Scientists have idenified that variation in a gene called Mucin 6 appears to indicate a tendency for acquiring Alzheimer’s disease.
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
New cell experiments show more effective genetic 'cuts' that could one day become the foundation of more effective gene therapies.
An AAV-delivered gene therapy has demonstrated success in animal models of temporal lobe epilepsy, so could be a therapeutic option for human patients.
A study has revealed that in rhesus monkeys, a genetic mutation could be the cause of Bardet-Biedl Syndrome, providing a way to study the disease and develop therapies.
A team has imaged the process that the body uses to stabilise DNA, which could be used to develop therapies for conditions such as cancer.
A new antiviral drug has been reported in a study that researchers believe has high clinical potential as a next-generation influenza drug.
